We prove that limit-periodic Dirac operators generically have spectra of zero Lebesgue measure and that a dense set of them have spectra of zero Hausdorff dimension. The proof combines ideas of Avila from a Schrödinger setting with a new commutation argument for generating open spectral gaps. This overcomes an obstacle previously observed in the literature; namely, in Schrödinger-type settings, translation of the spectral measure corresponds to small L ∞ -perturbations of the operator data, but this is not true for Dirac or CMV operators. The new argument is much more model-independent. To demonstrate this, we also apply the argument to prove generic zero-measure spectrum for CMV matrices with limit-periodic Verblunsky coefficients.
In 1935, Besicovitch proved a remarkable theorem indicating that an integrable function f on R 2 is strongly differentiable if and only if its associated strong maximal function M S f is finite a.e. We consider analogues of Besicovitch's result in the context of ergodic theory, in particular discussing the problem of whether or not, given a (not necessarily integrable) measurable function f on a nonatomic probability space and a measure preserving transformation T on that space, the ergodic averages of f with respect to T converge a.e. if and only if the associated ergodic maximal function T * f is finite a.e. Of particular relevance to this discussion will be recent results in the field of inhomogeneous diophantine approximation. Let f be an integrable function on R 2. A classical result in analysis, the Lebesgue Differentiation Theorem, tells us that, for a.e. x ∈ R 2 , the averages of f over disks shrinking to x tend to f (x) itself. More precisely, we have that lim r→0
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.